According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Those battling severe asthma, upper respiratory tract diseases, Chronic Obstructive Pulmonary Disease (COPD), Asbestosis and ...

“The brain is the gatekeeper of longevity,” said Wyss-Coray. “If you’ve got an old brain, you have an increased likelihood of ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

T-Mobile US Inc. has rolled back policies related to diversity, equity, and inclusion to appease the chairman of the Federal ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

A new study reveals that our organs age at different speeds, and those differences can predict future disease risk and even ...

Merck & Co. shares were climbing 3.1% in afternoon trading after the pharmaceutical giant announced a $10 billion deal to acquire respiratory-disease specialist Verona Pharma PLC. The deal adds Verona ...